Market Cap 201.50M
Revenue (ttm) 18.72M
Net Income (ttm) -132.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -705.50%
Debt to Equity Ratio 0.00
Volume 861,800
Avg Vol 1,146,050
Day's Range N/A - N/A
Shares Out 108.33M
Stochastic %K 25%
Beta 0.26
Analysts Strong Sell
Price Target $7.86

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JA...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 324 7933
Address:
701 Lee Road, Suite 103, Wayne, United States
StockDaddy68
StockDaddy68 Oct. 3 at 8:23 PM
$ACRS We finished up that's all that matters to me.
0 · Reply
Bionco
Bionco Oct. 3 at 3:45 PM
$ACRS I can't figure out what is wrong with this stock! It just simply can't hold a penny gain even though whole market is very bullish!
2 · Reply
StockDaddy68
StockDaddy68 Oct. 3 at 11:21 AM
0 · Reply
Djdanny
Djdanny Oct. 2 at 7:33 PM
$ACRS Tutes loading ↗️
0 · Reply
buymoremakemore
buymoremakemore Oct. 2 at 2:19 PM
$ACRS People will load up if this goes lower. We are fortunate to be full of catalysts the next 18 months
0 · Reply
StockDaddy68
StockDaddy68 Oct. 2 at 12:49 PM
0 · Reply
PepCF
PepCF Oct. 1 at 8:24 PM
$ACRS when moon?
0 · Reply
Bionco
Bionco Oct. 1 at 3:09 PM
$ACRS this is the third day ACRS is dessociated with XBI and whole market! Concerning even though fundamental is unchanged and strong!
0 · Reply
StockDaddy68
StockDaddy68 Oct. 1 at 1:34 PM
0 · Reply
Gated_Lambo
Gated_Lambo Oct. 1 at 12:39 PM
0 · Reply
Latest News on ACRS
Aclaris Therapeutics Announces Leadership Transition

Jul 28, 2025, 8:45 AM EDT - 2 months ago

Aclaris Therapeutics Announces Leadership Transition


Aclaris Therapeutics Announces $80 Million Private Placement

Nov 18, 2024, 8:10 AM EST - 11 months ago

Aclaris Therapeutics Announces $80 Million Private Placement


Aclaris Therapeutics Provides Corporate Update

Dec 19, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Provides Corporate Update


StockDaddy68
StockDaddy68 Oct. 3 at 8:23 PM
$ACRS We finished up that's all that matters to me.
0 · Reply
Bionco
Bionco Oct. 3 at 3:45 PM
$ACRS I can't figure out what is wrong with this stock! It just simply can't hold a penny gain even though whole market is very bullish!
2 · Reply
StockDaddy68
StockDaddy68 Oct. 3 at 11:21 AM
0 · Reply
Djdanny
Djdanny Oct. 2 at 7:33 PM
$ACRS Tutes loading ↗️
0 · Reply
buymoremakemore
buymoremakemore Oct. 2 at 2:19 PM
$ACRS People will load up if this goes lower. We are fortunate to be full of catalysts the next 18 months
0 · Reply
StockDaddy68
StockDaddy68 Oct. 2 at 12:49 PM
0 · Reply
PepCF
PepCF Oct. 1 at 8:24 PM
$ACRS when moon?
0 · Reply
Bionco
Bionco Oct. 1 at 3:09 PM
$ACRS this is the third day ACRS is dessociated with XBI and whole market! Concerning even though fundamental is unchanged and strong!
0 · Reply
StockDaddy68
StockDaddy68 Oct. 1 at 1:34 PM
0 · Reply
Gated_Lambo
Gated_Lambo Oct. 1 at 12:39 PM
0 · Reply
highnihilism
highnihilism Oct. 1 at 10:13 AM
$PFG Principal Financial Group Trade Count: 1 | Total $: 2 K | 0.14 × 90-Day Avg $: 13.8 K | Call $: 2 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $AMWD American Woodmark Trade Count: 6 | Total $: 2.1 K | 0.28 × 90-Day Avg $: 7.6 K | Call $: 2 K | Put $: 137 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $ACRS Aclaris Therapeutics Trade Count: 8 | Total $: 2 K | 0.85 × 90-Day Avg $: 2.4 K | Call $: 2 K | Put $: 31 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $KT KT Trade Count: 9 | Total $: 2 K | 0.85 × 90-Day Avg $: 2.3 K | Call $: 2 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
buymoremakemore
buymoremakemore Oct. 1 at 12:03 AM
$ACRS CRVS has been up big since July. Our time will come.
0 · Reply
Bionco
Bionco Sep. 30 at 6:30 PM
$ACRS WOW!
2 · Reply
StockDaddy68
StockDaddy68 Sep. 30 at 5:03 PM
$ACRS I just opened a position today. YEAY! Seems like a pretty decent company.
0 · Reply
Gated_Lambo
Gated_Lambo Sep. 30 at 12:30 PM
$ACRS https://finance.yahoo.com/news/aclaris-therapeutics-host-person-webcast-110000716.html
0 · Reply
Bionco
Bionco Sep. 29 at 6:22 PM
$ACRS From the2025 interim report of Sino biopharmaceuticals "TQC2731 (TSLP monoclonal antibody) is a humanized monoclonal antibody targeting TSLP, currently undergoing Phase III clinical trials in China. Its intended indications for development include severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease. It is the most rapidly developed domestically produced TSLP monoclonal antibody. Studies have shown that TSLP monoclonal antibody is not only effective in the treatment of eosinophilic asthma, but also shows significant efficacy in people with low eosinophilic phenotypes, so it can cover a wider range of patients with severe asthma. Currently, no TSLP monoclonal antibody has been approved for marketing in China. The Group will vigorously promote the clinical development of TQC2731 to address the unmet clinical needs."
0 · Reply
Gated_Lambo
Gated_Lambo Sep. 29 at 3:18 AM
$DTSS wow nice $FCHL $ACRS
2 · Reply
buymoremakemore
buymoremakemore Sep. 28 at 9:55 PM
$ACRS From Bionco. Maybe Im just not good at searching the ERS website. Maybe there was an abstract submission issue if phase 2 isnt there. Looks like there other upcoming conferences as long as we see some promising phase 2 data for an indication for ATI-045 then ATI-045 is majorly derisked
1 · Reply
buymoremakemore
buymoremakemore Sep. 28 at 9:19 PM
$ACRS you can see the poster online here for ATI-045. I guess they digitize the posters even before theyre presented. Looks like they presented phase 1 data as well.
3 · Reply
edvquye
edvquye Sep. 26 at 8:15 PM
$ACRS nice close!
0 · Reply
buymoremakemore
buymoremakemore Sep. 26 at 6:36 PM
$ACRS I believe between tomorrow and next week we will get to see full respiratory data at that conference. Thattl satisfy investors because someone can always start a phase 3 with noninferior data. Seeing full picture important a lot of times to move share price
1 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Sep. 26 at 6:26 PM
$ACRS some nice buys today …love this base building
0 · Reply